Kejal Kantarci, MD from the Mayo Clinic, Rochester, MN gives an overview on Alzheimer’s disease biomarkers at the Alzheimer’s Association International Conference (AAIC) 2017, London, UK. Dr Kantarci feels that more work needs to be done around alpha-synuclein including identification, ligand binding and CSF biomarkers. She also explains how the MRI field is increasingly being used to identify physical biomarkers that are linked to pathology relevant to clinical disease syndromes.
